Scisparc's board of directors provides strategic decision

Tel aviv, israel, june 09, 2022 (globe newswire) -- scisparc ltd. (nasdaq: sprc), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "company" or "scisparc"), today announced that the company's board of directors resolved to initiate a process to review potential strategic transactions with the goal of maximizing shareholder value.
SPRC Ratings Summary
SPRC Quant Ranking